ABSTRACT
Abciximab, Eptifibatide and Tirofiban are the three main glycoprotein IIb/IIIa receptor antagonists which have played a vital role in the field of cardiac medicine. They work by blocking the final mechanism of platelet aggregation pathway. These antagonists are widely used in treating acute coronary syndrome, myocardial infarction and during percutaneous coronary intervention (PCI). In this review, we have examined the chemistry, mechanism of action and clinical uses of these glycoprotein IIb/IIIa receptor antagonists. We also tried to study the binding mode of both eptifibatide and tirofiban with the glycoprotein IIb/IIIa receptors using molecular docking software. It appears that blocking the ASP 224 may be the cause for platelet activity inhibition.
ABSTRACT
OBJECTIVE:To establish an HPLC method for determination of major component and related peptide in eptifibatide injection.METHODS:The determination was performed on AichromBond-AQ C18 column with column temperature at 25 ℃ and flow rate of 1.0 mL?min-1.The mobile phase consisted of acetonitrile-water(0.13% trifluoroacetic acid).The detection wavelength was set at 220 nm and injection volume was 20 ?L.RESULTS:The linear range was 75.2～1 203.6 ?g?mL-1(r=0.9999) with mean recovery of 99.73%～99.95% (RSD=0.26%).CONCLUSION:The method is simple and rapid and it is applicable for determination of major component and related peptide in eptifibatide injection.